1e
19
1
49
2
2
18
1b
1d
18
43
59
1d 4 3 3 3 2 4 b 1f
2 29
1d
25
Kiran Musunuru, MD, PhD, MPH, ML, MRA
88
59
Barry J. Gertz Professor for Translational Research
28
d1
3
5f
Director, Penn Cardiovascular Institute's Genetic and Epigenetic Origins of Disease Program, Perelman School of Medicine at the University of Pennsylvania
a8
Scientific Director, Penn Center for Inherited Cardiovascular Disease, Hospital of the University of Pennsylvania
11
Department: Medicine
4
1
23
1f
Graduate Group Affiliations
8
a
b
1d 4 3 3 3 2 4 b 1f
13
Education:
21 7 AB 21 (Biochemical Sciences) c
37 Harvard College, Cambridge, MA, 1997.
21 8 PhD 20 (Biomedical Sciences) c
41 The Rockefeller University, New York, NY, 2003.
21 7 MD 15 (Medicine) c
44 Weill-Cornell Medical College, New York, NY, 2004.
21 8 MPH 19 (Epidemiology) c
57 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 2009.
21 7 ML 10 (Law) c
50 University of Pennsylvania Law School, Philadelphia, PA, 2019.
21 8 MRA 1f (Regulatory Affairs) c
68 Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2024.
c
3
3
3
3
8d
Permanent link21 7 AB 21 (Biochemical Sciences) c
37 Harvard College, Cambridge, MA, 1997.
21 8 PhD 20 (Biomedical Sciences) c
41 The Rockefeller University, New York, NY, 2003.
21 7 MD 15 (Medicine) c
44 Weill-Cornell Medical College, New York, NY, 2004.
21 8 MPH 19 (Epidemiology) c
57 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 2009.
21 7 ML 10 (Law) c
50 University of Pennsylvania Law School, Philadelphia, PA, 2019.
21 8 MRA 1f (Regulatory Affairs) c
68 Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2024.
c
2 29
21
1e
1d
24
2b
29
27
23
258 Shuvaev VV, Tam YK, Lee BW, Myerson JW, Herbst A, Kiseleva RY, Glassman PM, Parhiz H, Alameh MG, Pardi N, Muramatsu H, Shuvaeva TI, Arguiri E, Marcos-Contreras OA, Hood ED, Brysgel TV, Nong J, Papp TE, Eaton DM, Riley R, Palanki R, Musunuru K, Brenner JS, Mitchell MJ, Ferrari VA, Mui BL, Semple SC, Weppler SA, Atluri P, Margulies KB, Weissman D, Muzykantov VR.: Systemic delivery of biotherapeutic RNA to the myocardium transiently modulates cardiac contractility in vivo. Proc Natl Acad Sci U S A 122: e2409266122, Jul 2025.
2b5 Musunuru K, Grandinette SA, Wang X, Hudson TR, Briseno K, Berry AM, Hacker JL, Hsu A, Silverstein RA, Hille LT, Ogul AN, Robinson-Garvin NA, Small JC, McCague S, Burke SM, Wright CM, Bick S, Indurthi V, Sharma S, Jepperson M, Vakulskas CA, Collingwood M, Keogh K, Jacobi A, Sturgeon M, Brommel C, Schmaljohn E, Kurgan G, Osborne T, Zhang H, Kinney K, Rettig G, Barbosa CJ, Semple SC, Tam YK, Lutz C, George LA, Kleinstiver BP, Liu DR, Ng K, Kassim SH, Giannikopoulos P, Alameh MG, Urnov FD, Ahrens-Nicklas RC.: Patient-specific in vivo gene editing to treat a rare genetic disease. N Engl J Med 392: 2235-2243, Jun 2025.
1cd Urnov F, Kassim S, Musunuru K, Liu D, Lee A, Barrera L, Stetkiewicz P, Bruno J, Hewitt M, Lister T, Malech H, Gasch L, Diver M, Gertler N, Grignon F, Le A, Lehmicke M, Almendro-Navarro V, Lembong J.: Advancing gene-editing platforms to improve the viability of rare-disease therapeutics: key insights from a 2024 Scientific Exchange hosted by ARM, ISCT, and Danaher. Cytotherapy Jun 2025.
bd Musunuru K, Urnov F.: Moving Therapeutic Genome Editing into Global Clinical Trials and Medicine. CRISPR J May 2025.
a2 Musunuru K.: A milestone for gene-editing therapies. N Engl J Med 392: 508-509, Jan 2025.
13c Allyse MA, Agam P, Bombard Y, Feys R, Horstmann M, Kokayi A, Isasi R, Meagher KM, Michie M, Musunuru K, Ormond KE, Riggan KA, Yap JQ.: Building better medicine: translational justice and the quest for equity in US healthcare. Am J Bioeth 2025.
1a1 Kassim SH, Urnov F, Musunuru K, Lee A, Barrera L, Stetkiewicz P, Bruno J, Hewitt M, Lister T, Malech H, Gasch L, Diver M, Gertler N, Grignon F, Le A, Lehmicke M, Horwitz EM, Liu DR, Lembong J, Almendro-Navarro V.: Platform solutions for commercial challenges to expanding patient access and making gene editing sustainable. Nat Biotechnol 2025.
af IGVF Consortium: Deciphering the impact of genomic variation on function. Nature 633: 47-57, Sep 2024.
143 Riggan KA, Feys R, Kokayi A, Meagher KM, Michie M, Musunuru K, Ormond KE, Schelhaas AJ, Yap JQ, Isasi R, Allyse MA.: Grounded in reality: integrating community values and priorities of end users in human gene editing. Am J Bioeth 24: 43-45, Aug 2024.
2c
7
1d
1f
Selected Publications
e5 Gurevitz C, Bajaj A, Khera AV, Do R, Schunkert H, Musunuru K, Rosenson RS.: Gene therapy and genome editing for lipoprotein disorders. Eur Heart J Jul 2025.258 Shuvaev VV, Tam YK, Lee BW, Myerson JW, Herbst A, Kiseleva RY, Glassman PM, Parhiz H, Alameh MG, Pardi N, Muramatsu H, Shuvaeva TI, Arguiri E, Marcos-Contreras OA, Hood ED, Brysgel TV, Nong J, Papp TE, Eaton DM, Riley R, Palanki R, Musunuru K, Brenner JS, Mitchell MJ, Ferrari VA, Mui BL, Semple SC, Weppler SA, Atluri P, Margulies KB, Weissman D, Muzykantov VR.: Systemic delivery of biotherapeutic RNA to the myocardium transiently modulates cardiac contractility in vivo. Proc Natl Acad Sci U S A 122: e2409266122, Jul 2025.
2b5 Musunuru K, Grandinette SA, Wang X, Hudson TR, Briseno K, Berry AM, Hacker JL, Hsu A, Silverstein RA, Hille LT, Ogul AN, Robinson-Garvin NA, Small JC, McCague S, Burke SM, Wright CM, Bick S, Indurthi V, Sharma S, Jepperson M, Vakulskas CA, Collingwood M, Keogh K, Jacobi A, Sturgeon M, Brommel C, Schmaljohn E, Kurgan G, Osborne T, Zhang H, Kinney K, Rettig G, Barbosa CJ, Semple SC, Tam YK, Lutz C, George LA, Kleinstiver BP, Liu DR, Ng K, Kassim SH, Giannikopoulos P, Alameh MG, Urnov FD, Ahrens-Nicklas RC.: Patient-specific in vivo gene editing to treat a rare genetic disease. N Engl J Med 392: 2235-2243, Jun 2025.
1cd Urnov F, Kassim S, Musunuru K, Liu D, Lee A, Barrera L, Stetkiewicz P, Bruno J, Hewitt M, Lister T, Malech H, Gasch L, Diver M, Gertler N, Grignon F, Le A, Lehmicke M, Almendro-Navarro V, Lembong J.: Advancing gene-editing platforms to improve the viability of rare-disease therapeutics: key insights from a 2024 Scientific Exchange hosted by ARM, ISCT, and Danaher. Cytotherapy Jun 2025.
bd Musunuru K, Urnov F.: Moving Therapeutic Genome Editing into Global Clinical Trials and Medicine. CRISPR J May 2025.
a2 Musunuru K.: A milestone for gene-editing therapies. N Engl J Med 392: 508-509, Jan 2025.
13c Allyse MA, Agam P, Bombard Y, Feys R, Horstmann M, Kokayi A, Isasi R, Meagher KM, Michie M, Musunuru K, Ormond KE, Riggan KA, Yap JQ.: Building better medicine: translational justice and the quest for equity in US healthcare. Am J Bioeth 2025.
1a1 Kassim SH, Urnov F, Musunuru K, Lee A, Barrera L, Stetkiewicz P, Bruno J, Hewitt M, Lister T, Malech H, Gasch L, Diver M, Gertler N, Grignon F, Le A, Lehmicke M, Horwitz EM, Liu DR, Lembong J, Almendro-Navarro V.: Platform solutions for commercial challenges to expanding patient access and making gene editing sustainable. Nat Biotechnol 2025.
af IGVF Consortium: Deciphering the impact of genomic variation on function. Nature 633: 47-57, Sep 2024.
143 Riggan KA, Feys R, Kokayi A, Meagher KM, Michie M, Musunuru K, Ormond KE, Schelhaas AJ, Yap JQ, Isasi R, Allyse MA.: Grounded in reality: integrating community values and priorities of end users in human gene editing. Am J Bioeth 24: 43-45, Aug 2024.
2c